Tumor cells lacking NAPRT1, on the other hand, rely on NAMPT (the rate-limiting enzyme in salvage pathway) to create NAD and support cell survival, thus making them more vulnerable to NAMPT inhibitors (Olesen et al., 2010). The gene discussed is NAMPT; the disease is neoplasm.